<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110103005536N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-11</date_registration>
      <primary_sponsor>Artesh University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of fibroptic bronchoscopic with two method: midazolam base versus lidocaine base</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of fibroptic bronchoscopic with two method: midazolam base versus lidocaine base in patients refered at lung clinic in AJA 501 hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50426</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned between the two groups (70 people in each group) by Simple Random Sampling method using black and white cards, so that patients with black card to group one, and patients with white card to Group two is assigned and this process is repeated again, Blinding description: In this study, neither the patient nor the collector knew how the samples were distributed. The obtained information is then statistically analyzed by the person in charge of statistical work who does not know how the patients are distributed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>bronchoscopy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In one group, for performing fibropeptic bronchoscopy, the method of anesthesia is used based on "midazolam". It is administered intravenously and after the fibroptic bronchoscope enters the patient's mouth and before passing through the vocal cords with a syringe with a volume of 5 cc of distilled water is poured on the vocal cords (through the place of fluid entry in the bronchoscope) and then After passing the bronchoscope through the vocal cords, a syringe with a volume of 5 cc of distilled water is poured into the patient's trachea (tracheobronchial tree). Intervention 2: Intervention group: In one group, for performing fibropeptic bronchoscopy, the method of anesthesia based on "lidocaine" is used. A syringe containing 5 cc of lidocaine (2% lidocaine) is used intravenously and after entering the fibroptic bronchoscope. Patient and before passing the vocal cords with a syringe with a volume of 5 cc lidocaine 2% is poured on the vocal cords (through the place of fluid entry in the bronchoscope) and after passing the bronchoscope through the vocal cords with a syringe With a volume of 5 cc of 2% lidocaine is poured into the patient's trachea (tracheobronchial tree).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after it is unrecognizable

When:
Start the access period after printing the results

To whom:
All researchers and colleagues in this field

Conditions:
For therapeutic-research purposes and by mentioning the names of the authors of the article

Where to obtain:
Dr. mohammadreza rafiei

How to obtain:
Sending an Email to Dr. mohammadreza rafiei and receive data and documentation if needed in the shortest time

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mohammadreza Rafiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Etemadzadeh St., West Fatemi Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8158177365</zip>
        <telephone>+98 31 3261 6302</telephone>
        <email>mo_rafiei@armyums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mohammadreza Rafiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Etemadzadeh St., West Fatemi Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8158177365</zip>
        <telephone>+98 31 3261 6302</telephone>
        <email>mo_rafiei@armyums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>male and female patients aged 18 to 80 years
ASA  I-II</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>People with a history of sore throat and lung disease with 90% o2sat (hypoxemia)
People with Ejection fraction less than 40%
people with hearth rate less than 50
people with hypotension less than 90 mmHg
People with III and grade II conduction blocks
People with liver failure (2-fold increase in liver enzymes) and kidney failure (creatinine more than 2 mg / dL)
Pregnant or lactating women
People With a history of long-term use of antipsychotic drugs or sedatives.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In one group, for performing fibropeptic bronchoscopy, the method of anesthesia is used based on "midazolam". It is administered intravenously and after the fibroptic bronchoscope enters the patient's mouth and before passing through the vocal cords with a syringe with a volume of 5 cc of distilled water is poured on the vocal cords (through the place of fluid entry in the bronchoscope) and then After passing the bronchoscope through the vocal cords, a syringe with a volume of 5 cc of distilled water is poured into the patient's trachea (tracheobronchial tree).</i_keyword>
      <i_keyword>Intervention group: In one group, for performing fibropeptic bronchoscopy, the method of anesthesia based on "lidocaine" is used. A syringe containing 5 cc of lidocaine (2% lidocaine) is used intravenously and after entering the fibroptic bronchoscope. Patient and before passing the vocal cords with a syringe with a volume of 5 cc lidocaine 2% is poured on the vocal cords (through the place of fluid entry in the bronchoscope) and after passing the bronchoscope through the vocal cords with a syringe With a volume of 5 cc of 2% lidocaine is poured into the patient's trachea (tracheobronchial tree).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Type of basic anesthetic. Timepoint: Before the intervention. Method of measurement: Based on the name of the drug.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Complications of bronchoscopy. Timepoint: During the intervention. Method of measurement: Based on the need for intubation, nausea, decreased oxygen saturation, sore throat, cough.</sec_outcome>
      <sec_outcome>Duration of bronchoscopy. Timepoint: During the intervention. Method of measurement: Based on time from start to end of the procedure.</sec_outcome>
      <sec_outcome>Physician satisfaction. Timepoint: After the intervention. Method of measurement: Based on the doctor's satisfaction with the procedure from 1 to 5 based on likret scale.</sec_outcome>
      <sec_outcome>Patient satisfaction. Timepoint: After the intervention. Method of measurement: Based on the patient's satisfaction with the procedure from 1 to 5 based on likret scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Artesh University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-04-28</approval_date>
        <contact_name>Ethics committee of aja univercity of medical sciences</contact_name>
        <contact_address>Etemadzadeh St., West Fatemi Ave. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
